Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anti-H1 in dermatological practice].

C Gaudy-Marqueste1, J-J Grob, M-A Richard

  • 1Service de Dermatologie et Vénérologie, Hôpital Sainte Marguerite, 270, boulevard Sainte-Marguerite, 13009 Marseille.

Annales De Dermatologie Et De Venereologie
|July 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C.

ESMO open·2026
Same author

A case of bullous fixed drug eruption induced by tenofovir disoproxil fumarate/ emtricitabine.

Annales de dermatologie et de venereologie·2026
Same author

Use of social media and alternative and complementary medicine in a cohort of 1053 patients with hidradenitis suppurativa.

Annales de dermatologie et de venereologie·2026
Same author

Risk of persistent hypogammaglobulinaemia in children with autoimmune bullous dermatoses treated with rituximab.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Prevalence of tattoos in a cohort of 1053 patients with hidradenitis suppurativa.

Annales de dermatologie et de venereologie·2025
Same author

Withdrawal of biologic agents before pregnancy is associated with psoriasis flare.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same journal

2024 guidelines (S3) for the therapeutic management of patients with genital herpes.

Annales de dermatologie et de venereologie·2026
Same journal

Topical JAK inhibitors in the lichen planus spectrum: a systematic review.

Annales de dermatologie et de venereologie·2026
Same journal

2024 recommendations for the therapeutic management of anogenital warts.

Annales de dermatologie et de venereologie·2026
Same journal

Successful use of thalidomide in treating metastatic Crohn's disease.

Annales de dermatologie et de venereologie·2026
Same journal

Multiple cutaneous juvenile xanthogranuloma: a monocentric study.

Annales de dermatologie et de venereologie·2026
Same journal

Cartilage-hair-hypoplasia associated with granulomatosis induced by rubella vaccine.

Annales de dermatologie et de venereologie·2026
See all related articles

Second-generation anti-histamines (anti-H1s) are effective for treating skin diseases like urticaria. These newer antihistamines offer better side effect profiles and pharmacokinetics compared to older first-generation options.

Area of Science:

  • Pharmacology
  • Dermatology
  • Allergology

Context:

  • Histamine plays a key role in allergic reactions and dermatological conditions.
  • Anti-histamines (anti-H1s) counteract histamine's effects at its receptors.
  • Two generations of anti-H1s exist: first and second generation.

Purpose:

  • To evaluate the effectiveness of anti-H1 medications in treating various skin diseases.
  • To compare the efficacy and safety of different generations of anti-H1s.

Summary:

  • Evidence confirms anti-H1 efficacy in specific dermatitis and urticaria.
  • Urticaria is identified as a primary indication for anti-H1 treatment.
  • Second-generation anti-H1s are recommended over first-generation due to fewer side effects and better pharmacokinetics.

Related Experiment Videos

Impact:

  • Provides evidence-based recommendations for using anti-histamines in dermatology.
  • Highlights the preference for second-generation anti-H1s for improved patient outcomes.
  • Supports the symptomatic use of anti-H1s in managing various dermatitis conditions.